Stockreport

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases [Yahoo! Finance]

Kazia Therapeutics Limited - American Depositary Shares  (KZIA) 
US:NASDAQ Investor Relations: kaziatherapeutics.com
PDF announce that it has entered into an exclusive licensing agreement with Sovargen Co., Ltd, a biotechnology company specializing in central nervous system (CNS) diseases, [Read more]